Loading clinical trials...
Loading clinical trials...
A Phase 1, Open-label Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral EPI-7386 in Patients with Castration-Resistant Prostate Cancer
Conditions
Interventions
EPI-7386 (QD)
EPI-7386 (BID)
+2 more
Locations
9
United States
Hematology Oncology Associates of the Treasure Coast
Port Saint Lucie, Florida, United States
Winship Cancer Institute of Emory University
Atlanta, Georgia, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Washington University School of Medicine in St. Louis
St Louis, Missouri, United States
Comprehensive Cancer Center of NV Las Vegas
Las Vegas, Nevada, United States
Great Lakes Cancer Center
Buffalo, New York, United States
Start Date
June 23, 2020
Primary Completion Date
October 31, 2024
Completion Date
December 3, 2024
Last Updated
February 28, 2025
NCT06594926
NCT06257264
NCT03620786
NCT04693377
NCT05424783
NCT06334120
Lead Sponsor
ESSA Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions